Biotech | May 02, 2022
CIVCO Radiotherapy to Unveil TotalRT All in One Solution at ESTRO 2022
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Ivabradine Tablets, 5 mg and 7.5 mg have an estimated market size of US $ 102 million for twelve months ending December 2021 according to IQVIA
No new studies have been requested
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Subscribe To Our Newsletter & Stay Updated
